Lembo G, Raulo U, Cantelli V, Patruno C, [Dermatographic urticaria: evaluation of the therapeutic efficacy of drugs using a dermatographic tester], in G Ital Dermatol Venereol, vol. 122, n. 12, dicembre 1987, pp. 671–4, PMID3129367.
(DE) Tóth-Kása I, Husz S, [Combined pizotiphen and cinnarizine treatment in urticaria factitia], in Z. Hautkr., vol. 62, n. 4, febbraio 1987, pp. 325–9, PMID3577293.
Neittaanmäki H, Myöhänen T, Fräki JE, Comparison of cinnarizine, cyproheptadine, doxepin, and hydroxyzine in treatment of idiopathic cold urticaria: usefulness of doxepin, in J. Am. Acad. Dermatol., vol. 11, n. 3, settembre 1984, pp. 483–9, PMID6480953.
(UK) Mitiuriaieva IO, Maĭdannyk VH, [Efficacy of the pharmacotherapy of secondary enuresis in children], in Lik. Sprava, n. 3, 2007, pp. 70–6, PMID18271185.
(RU) Kozlovskiĭ VL, [The influence of calcium channel blockers on the effects of anxiogenic preparations], in Patol Fiziol Eksp Ter, n. 3, 2000, pp. 3–4, PMID10983469.
(RU) Kozlovskiĭ VL, Mosin AE, Ivakina LV, [The effect of calcium channel blockers on anxiety evoked by amputation of the vibrissae in rats], in Eksp Klin Farmakol, vol. 60, n. 1, 1997, pp. 10–2, PMID9162271.
(RU) Kozlovskiĭ VL, Mosin AE, Ivakina LV, [The effect of the subchronic administration of calcium-channel blockers on CNS excitability], in Eksp Klin Farmakol, vol. 59, n. 1, 1996, pp. 14–6, PMID8704622.
(RU) Kozlovskiĭ VL, Prakh'e IV, [The effect of calcium channel blockers on animal behavior in tests to study their anxiolytic activity], in Eksp Klin Farmakol, vol. 58, n. 1, 1995, pp. 18–20, PMID7787686.
S. Miyagawa, H. Ohi; T. Muramatsu; T. Okuchi; T. Shirai; K. Sakamoto, Lichen planus pemphigoides-like lesions induced by cinnarizine., in Br J Dermatol, vol. 112, n. 5, maggio 1985, pp. 607-13, PMID3890919.
PE. Stoebner, C. Michot; C. Ligeron; L. Durand; J. Meynadier; L. Meunier, [Simvastatin-induced lichen planus pemphigoides], in Ann Dermatol Venereol, vol. 130, 2 Pt 1, febbraio 2003, pp. 187-90, PMID12671581.
A. Toll, P. Campo-Pisa; J. González-Castro; A. Campo-Voegeli; A. Azón; P. Iranzo; M. Lecha; C. Herrero, Subacute cutaneous lupus erythematosus associated with cinnarizine and thiethylperazine therapy., in Lupus, vol. 7, n. 5, 1998, pp. 364-6, PMID9696142.
T. Rufli, [Demonstrations], in Dermatologica, vol. 159, n. 5, 1979, pp. 413-22, PMID488500.
W. Brenner, F. Gschnait, [Cinnarizin--an up to now unrecognized inducer of a lupus erythematosus-like syndrome], in Hautarzt, vol. 29, n. 7, luglio 1978, pp. 392-4, PMID681178.
M. Louter, SC. Tromp, [Parkinsonism due to the medication], in Ned Tijdschr Geneeskd, vol. 153, 2009, pp. A336, PMID19900308.
T. Brücke, C. Wöber; I. Podreka; C. Wöber-Bingöl; S. Asenbaum; S. Aull; S. Wenger; D. Ilieva; C. Harasko-van der Meer; P. Wessely, D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study., in J Cereb Blood Flow Metab, vol. 15, n. 3, maggio 1995, pp. 513-8, PMID7714010.
S. Giménez-Roldán, D. Mateo, Cinnarizine-induced parkinsonism. Susceptibility related to aging and essential tremor., in Clin Neuropharmacol, vol. 14, n. 2, aprile 1991, pp. 156-64, PMID2015612.
JR. Daniel, VF. Mauro, Extrapyramidal symptoms associated with calcium-channel blockers., in Ann Pharmacother, vol. 29, n. 1, gennaio 1995, pp. 73-5, PMID7711350.